Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate

AstraZeneca’s $1 billion bet on Daiichi Sankyo’s TROP2 antibody-drug conjugate (ADC) delivered promising early-phase breast cancer data. Chasing Gilead, the partners have linked the TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) to response and survival results that suggest they have a shot at coming from behind to disrupt the market.